Protara Therapeutics (TARA) Profit After Tax (2013 - 2026)
Protara Therapeutics' (TARA) quarterly Profit After Tax came in at -$17.8 million in Q1 2026, down 49.25% year-on-year from -$35.0 million in Q1 2025, and down 2.74% on a QoQ basis from -$17.3 million in Q4 2025.
Protara Therapeutics (TARA) Profit After Tax (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has 14 years of Profit After Tax data on file, last reported at -$17.8 million in Q1 2026.
- On a quarterly basis, Profit After Tax fell 49.25% year-over-year to -$17.8 million in Q1 2026; TTM through Mar 2026 was -$63.3 million, a 39.3% decrease from a year earlier, with the FY2025 full-year figure at -$57.4 million, down 28.8% from the prior year.
- Profit After Tax for Q1 2026 stood at -$17.8 million, down from -$17.3 million in the prior quarter.
- Over the last five years, Profit After Tax for TARA reached as high as -$7.7 million in Q3 2022 and fell as low as -$39.0 million in Q4 2022.
- Historically, Profit After Tax has averaged -$13.3 million across 5 years, with a median of -$11.2 million in 2024.
- Across the five-year window, Profit After Tax slumped 274.68% in 2022 and surged 75.46% in 2023, its largest moves.
- Year by year, Profit After Tax stood at -$39.0 million in 2022, then jumped by 75.46% to -$9.6 million in 2023, then tumbled by 34.14% to -$12.8 million in 2024, then slumped by 34.91% to -$17.3 million in 2025, then slipped by 2.74% to -$17.8 million in 2026.
- Per Business Quant data, the three most recent Profit After Tax figures were -$17.8 million in Q1 2026, -$17.3 million in Q4 2025, and -$13.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Protara Therapeutics | 233.61 Mn | 233.61 Mn | - | -17.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.78 Mn |
| Dec 31, 2025 | -17.31 Mn |
| Sep 30, 2025 | -13.26 Mn |
| Jun 30, 2025 | -14.96 Mn |
| Mar 31, 2025 | -11.91 Mn |
| Dec 31, 2024 | -12.83 Mn |
| Sep 30, 2024 | -11.19 Mn |
| Jun 30, 2024 | -9.51 Mn |
| Mar 31, 2024 | -11.10 Mn |
| Dec 31, 2023 | -9.56 Mn |
| Sep 30, 2023 | -9.86 Mn |
| Jun 30, 2023 | -11.29 Mn |
| Mar 31, 2023 | -9.05 Mn |
| Dec 31, 2022 | -38.97 Mn |
| Sep 30, 2022 | -7.70 Mn |
| Jun 30, 2022 | -8.54 Mn |
| Mar 31, 2022 | -10.76 Mn |
| Dec 31, 2021 | -10.40 Mn |
| Sep 30, 2021 | -10.72 Mn |
| Jun 30, 2021 | -12.78 Mn |